Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levoamphetamine is the levorotatory isomer of amphetamine, a central nervous system stimulant that acts as a sympathomimetic agent. While its dextrorotatory counterpart, dextroamphetamine, is more potent in stimulating dopamine release, levoamphetamine exhibits a stronger relative affinity for the norepinephrine system and has a longer half-life. Cognition Therapeutics developed C105 (levoamphetamine sulfate) as a potential treatment for cognitive impairment associated with multiple sclerosis (MS), aiming to improve processing speed and memory deficits. Its mechanism of action involves the release of catecholamines (norepinephrine and dopamine) from presynaptic terminals and the inhibition of their reuptake, primarily mediated through the activation of the trace amine-associated receptor 1 (TAAR1) and interaction with monoamine transporters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levoamphetamine.